The company said net revenues for Q2 2024 were $2,397 million, up 2.5% from Q2 2023 $2,338 million. Reported diluted EPS was $2.03, down 1.0%, and adjusted diluted EPS was $2.35, up 2.2%.

1. 01

   The company said net revenues for Q2 2024 were $2,397 million, up 2.5% from Q2 2023 $2,338 million. Reported diluted EPS was $2.03, down 1.0%, and adjusted diluted EPS was $2.35, up 2.2%.

2. 02

   Quest Diagnostics set its full-year 2024 net revenue outlook at $9.50 billion to $9.58 billion (prior outlook $9.40 billion to $9.48 billion). Its adjusted diluted EPS outlook is $8.80 to $9.00 (prior outlook $8.72 to $8.97).

3. 03

   The company said its operating cash flow for the six months ended 2024 was $514 million (6 months of 2023: $538 million), and that it paid $301 million in debt repayments over the same period. Cash and cash equivalents stood at $271 million as of June 30, 2024.

4. 04

   The company cited four acquisitions: the planned acquisition of LifeLabs, the announced acquisition of select outreach lab assets of Allina Health and OhioHealth, and the recently completed PathAI Diagnostics acquisition. The company said it expects to complete the LifeLabs transaction by the end of the year and that its updated guidance does not include the impact of that transaction.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.